Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
CRISPR Therapeutics AG

CRISPR Therapeutics AG (CRSP) Stock Overview

Explore CRISPR Therapeutics AG’s financial performance, market position, analyst ratings, and future outlook.

CRSP●NASDAQ
HealthcareBiotechnology
$59.50
$0.31(0.52%)
U.S. Market opens in 63h 26m

CRISPR Therapeutics AG (CRSP)

Meyka AI Score

Z

Key Financials

Market Cap5.6B
P/E Ratio-12.55
EPS (TTM)$-4.76
ROE-0.24%
Fundamental Analysis

AI Price Forecasts

1 Month$62.10
3 Months$59.25
1 Year Target$45.44

CRSP Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of CRISPR Therapeutics AG (NASDAQ: CRSP) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, CRISPR Therapeutics AG's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of CRSP on the NASDAQ shows an RSI of 67.20, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $45.44 for the NASDAQ listing.

Key metrics behind CRISPR Therapeutics AG's NASDAQ-traded stock include a P/E ratio of -12.55 and a market capitalization of 5.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CRSP on the NASDAQ.

Price Performance (NASDAQ: CRSP)

1-Day Change
2.37%
5-Day Change
10.21%
1-Month Change
23.57%
3-Month Change
19.24%
6-Month Change
11.30%
Year-to-Date (YTD) Change
13.46%
1-Year Change
12.65%
3-Year Change
24.14%
5-Year Change
-52.41%
All-Time (Max) Change
322.29%

Contact Information

https://www.crisprtx.com
41 41 561 32 77
Baarerstrasse 14, Zug, ZG, 6300

Company Facts

3,930 Employees
IPO DateOct 19, 2016
CountryCH
Actively Trading

Frequently Asked Questions